Abstract:Inflammatory bowel disease (IBD) is a global health problem in which gut microbiota dysbiosis plays an important pathogenic role. However, the current drugs for IBD treatment are far from optimal. Previous researches indicated that parthenolide (PTL) had not only anti-cancer properties but also strong anti-inflammatory activities.Rationale: To investigate the protective effect of PTL on colon inflammation and demonstrate the underlying gut microbiota-dependent mechanism.Methods: Colon inflammation severity in mouse model was measured by body weight change, mortality, colon length, disease activity index (DAI) score, H&E staining and colonoscopy evaluation. Gut microbiota alteration and short-chain fatty acids (SCFAs) production were analyzed through 16S rRNA sequencing and targeted metabolomics. Luminex cytokine microarray and Enzyme-linked immunosorbent assay (ELISA) were conducted to measure the colon cytokines profile. The frequency of immune cells in lamina propria (LP) and spleen were phenotyped by flow cytometry.Results: The PTL-treated mice showed significantly relieved colon inflammation, as evidenced by a reduction in body weight loss, survival rate, shortening of colon length, DAI score, histology score and colonoscopy score. Notably, when the gut microbiota was depleted using antibiotic cocktails, the protective effect of PTL on colon inflammation disappeared. PTL treatment downregulated the level of proinflammatory cytokines, including IL-1β, TNF-α, IL-6, and IL-17A and upregulated the immunosuppressive cytokine IL-10 in colon tissue. 16S rRNA sequencing indicated that PTL-treated mice exhibited much more abundant gut microbial diversity and flora composition. Targeted metabolomics analysis manifested the increased SCFAs production in PTL-treated mice. Additionally, PTL administration selectively upregulated the frequency of colonic regulatory T (Treg) cells as well as downregulated the ratio of colonic T helper type 17 (Th17) cells, improving the Treg/Th17 balance to maintain intestinal homeostasis. Gut microbiota depletion and fecal microbiota transplantation (FMT) was performed to confirm this gut microbiota-dependent mechanism.Conclusions: PTL ameliorated colon inflammation in a gut microbiota-dependent manner. The underlying protective mechanism was associated with the improved Treg/Th17 balance in intestinal mucosa mediated through the increased microbiota-derived SCFAs production. Collectively, our results demonstrated the role of PTL as a potential gut microbiota modulator to prevent and treat IBD.

Parthenolide targets NLRP3 to treat inflammasome-related diseases

Tetrastigma Hemsleyanum Tubers Polysaccharide Ameliorates LPS-induced Inflammation in Macrophages and Caenorhabditis Elegans.

Parthenolide ameliorates colon inflammation through regulating Treg/Th17 balance in a gut microbiota-dependent manner

Medicinal Plants and Bioactive Natural Products As Inhibitors of NLRP3 Inflammasome

The Therapeutic Effect and Mechanism of Parthenolide in Skeletal Disease, Cancers, and Cytokine Storm

Parthenolide, bioactive compound of Chrysanthemum parthenium L., ameliorates fibrogenesis and inflammation in hepatic fibrosis via regulating the crosstalk of TLR4 and STAT3 signaling pathway

Parthenolide alleviates microglia‐mediated neuroinflammation via MAPK/TRIM31/NLRP3 signaling to ameliorate cognitive disorder

Parthenolide Inhibits Synthesis and Promotes Degradation of Programmed Cell Death Ligand 1 and Enhances T Cell Tumor-Killing Activity

Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders

Discovery of Novel Pterostilbene-Based Derivatives as Potent and Orally Active NLRP3 Inflammasome Inhibitors with Inflammatory Activity for Colitis

Recent Progress on the Discovery of NLRP3 Inhibitors and their Therapeutic Potential

1,2,4-Trimethoxybenzene selectively inhibits NLRP3 inflammasome activation and attenuates experimental autoimmune encephalomyelitis

New Applications of Clioquinol in the Treatment of Inflammation Disease by Directly Targeting Arginine 335 of NLRP3

Targeting the NLRP3 inflammasome as new therapeutic avenue for inflammatory bowel disease

Pharmacological Inhibitors of the NLRP3 Inflammasome

Phenols and terpenoids: natural products as inhibitors of NLRP3 inflammasome in cardiovascular diseases

Natural products modulate NLRP3 in ulcerative colitis

Britannin as a novel NLRP3 inhibitor, suppresses inflammasome activation in macrophages and alleviates NLRP3-related diseases in mice

Discovery of alantolactone as a natural NLRP3 inhibitor to alleviate NLRP3‐driven inflammatory diseases in mice

Specific Nlrp3 Inflammasome Inhibitors: Promising Therapeutic Agents For Inflammatory Diseases

Parthenolide inhibits the proliferation and migration of cervical cancer cells via FAK/GSK3β pathway